Sopharma's Non-Consolidated Profit Up 37% Y/Y

Sopharma ()  posted Jan – Sept profit in the amount of 25.980 mln leva (13.283 mln euros), or 37.4% more than the 18.910 mln leva (9.668 mln euros) a year ago, the pharmaceutical company's non-consolidated September 30 report. Profit grew 35% compared with H1 results. We remind that on June 30, it stood at 19.152 mln leva (5.006 mln euros).

Revenues came to 124.247 mln leva (63.526 mln euros), versus 111.754 mln leva (57.138 mln euros) a year ago. Of these 121.840 mln leva is revenue from core activity, which is 17.210 mln leva more than last year. Production sales resulted in 110.009 mln leva, versus 94.214 mln leva last year.

Revenue on the domestic market grew by nearly 1 mln leva to 47.591 mln leva. Export revenues came to 62.418 mln leva, or by 14.687 mln leva up from last year.

Positive difference from operations with foreign currency came to 4.403 mln leva.

Activity costs grew by 5.863 mln leva and on September 30 stood at 95.370 mln leva (48.761 mln euros). Costs on economic elements are in the amount of 88.892 mln leva, versus 81.118 mln leva. Costs on materials shrank by nearly 4 mln leva to 28.708 mln leva. Sopharma spent 31.116 mln leva for external services, which is by 6.8 mln leva more than last year.

The company controls assets in the amount of 317.772 mln leva (162.474 mln euros), versus 282.780 mln leva (144.583 mln euros) a year ago. Fixed assets rose by 20.3 mln leva to 160.760 mln leva. The company controls machines and equipment worth 93.779 mlnleva.

The company invested 50.315 mln leva in its subsidiaries during the period, which is by nearly 10 mln leva more than in the first nine months of 2006. Sopharma also invested 5.404 mln leva in affiliated companies.

Sopharma's core capital stands at 132 mln leva (67.490 mln euros), and it sown capital is at 196.742 mln leva (100.592 mln euros).

The company's subsidiaries are Sopharma Trading (99.62%), Bulgarian Rose Sevtopolis (49%), Farmachim Holding (100%), Farmalogistics (76.54%), Rostbalkanpharm (51%), NIHFI (46%), Electroncommerce (100%), Biopharm Engineering (51%), Sopharma Poland (60%), Sopharma USA (100%), Mineralcommerce (51%).

Affiliated companies are Momina Krepost and Sopharma Logistics. The company holds investments in Doverie United Holding, Sopharma Properties REIT, Medica JSC, Kaliman RT, Lavena JSC, Sopharma Building REIT, Ecobulpac, Sopharma Trading 2006, HVB Nank Biochim, and Maritzatex.

Shares rose 2.07% to an average of 9.39 leva at a turnover of 67,603 shares.

Facebook Коментари

Добави коментар

Екипът на Ви благодари, че използвате кирилица за вашите коментари.
В случай, че коментарът Ви съдържа нецензурни квалификации и лични нападки или обиди на расова, сексуална, етническа или верска основа, той ще бъде изтрит от модератора на сайта.

Абонирайте се за електронния
информационен бюлетин на